Hdl Cholesterol

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events.

CHICAGO — When race was removed from the MESA risk prediction score, its ability to predict risk for heart disease did not change significantly, researchers reported at the American Heart Association Scientific Sessions.

PHILADELPHIA — HDL cholesterol has not been shown to have a causal role in atherosclerotic cardiovascular disease, nor has lowering it reduced CV outcomes, but it may serve as a marker for CVD risk, according to a speaker.

Improving HDL function may improve outcomes after acute MI for patients with multivessel disease and high LDL, according to a subanalysis of the AEGIS II trial presented at the National Lipid Association Scientific Sessions.

ATLANTA — Monthly administration of subcutaneous olezarsen substantially reduced triglyceride levels compared with placebo among patients with predominantly moderate hypertriglyceridemia and elevated CV risk, according to new phase 2 data.

ATLANTA — Four weekly infusions of a novel formulation of human apolipoprotein A-I did not reduce a combination of CV endpoints at 90 days for adults with acute MI, multivessel disease and additional CV risk factors, researchers reported.

Elevated lipid levels were associated with worsening structural and functional cardiac damage in adolescents and young adults, though in the case of LDL, the relationship was partially mediated by elevated BP and fat mass, data show.

DALLAS — In this Healio video exclusive, Michael S. Irwig, MD, discusses how gender-confirming hormone therapy may affect obesity and cardiometabolic health.